OmniAb Stock News

OmniAb, Inc. (NASDAQ:OABI ) Q4 2024 Earnings Conference Call March 18, 2025 4:30 PM ET Company Participants Kurt Gustafson - Chief Financial Officer Matt Foehr - President & Chief Executive Officer Conference Call Participants Joe Pantginis - H.C. Wainwright Kripa Devarakonda - Truist Securities Operator Good afternoon and welcome to OmniAb Inc's Fourth Quarter and Full Year 2024 Financial Resu...

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2024, and provided operating and partner program updates. “2024 was a remarkable year featuring double-digit percentage growth in the number of both active partners and programs. Clinical-stage programs advanced well, and we launched new technologies a...

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and 12 months ended December 31, 2024 after the close of the U.S. financial markets on Tuesday, March 18, 2025 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What:   OmniAb conference call to discuss fourth quart...

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in two investor conferences during the month of March. TD Cowen 45th Annual Health Care Conference, March 3-5 at the Boston Marriott Copley Place. Management will be presenting a corporate overview on Tuesday, March 4th at 2:30 p.m. Eastern time and will be holding one-on-one m...

NEW YORK , Jan. 31, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of OmniAb, Inc. (NASDAQ: OABI) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced that two presentations featuring the Company's technologies were delivered at the 2024 Antibody Engineering & Therapeutics Conference (AETC) underway in San Diego. In a presentation titled “Building Multispecifics from in vivo Derived Antibody Domains and Alternative Scaffolds,” Yasmina Abdiche, Ph.D., Vice Preside...

OmniAb, Inc. (NASDAQ:OABI ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Kurt Gustafson - Chief Financial Officer Matt Foehr - President & Chief Executive Officer Conference Call Participants Stephen Willey - Stifel Alex Xenakis - Truist Securities Jacqueline Kisa - TD Cowen Conor McNamara - RBC Capital Markets Operator Good afternoon, and welcome to OmniAb...

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and nine months ended September 30, 2024, and provided operating and partner program updates. “We are pleased to report another successful quarter demonstrating our continued commitment to innovation with the expansion of our technology platform and a growing partnership portfolio. Th...